James Bearden to Paclitaxel
This is a "connection" page, showing publications James Bearden has written about Paclitaxel.
Connection Strength
0.133
-
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol. 2003 May 15; 21(10):2004-10.
Score: 0.055
-
A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. J Thorac Oncol. 2015 Jan; 10(1):172-80.
Score: 0.031
-
Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914. J Thorac Oncol. 2006 Nov; 1(9):991-5.
Score: 0.017
-
Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer. 2005 Jun 01; 103(11):2298-303.
Score: 0.016
-
A phase II trial of preoperative concurrent radiation therapy and weekly paclitaxel/carboplatin for patients with locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2004 Jul; 6(1):33-42.
Score: 0.015